Imagion Biosystems Limited has announced Appendix 3B, “New issue announcement, application for quotation of additional securities and agreement.”
Read Appendix 3B.
Quarterly Activity Report – Quarter ending 31 December 2023
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal